

Please add the following new claims 25-42:

---

25. A conjugate comprising:

(a) a first region comprising the homeodomain of antennapedia or a functional variant thereof; and

(b) a second region not naturally associated with the first region, wherein the second region comprises a protein of at least 100 amino acids; and wherein at least the first region is non-denatured.

26. The conjugate according to claim 25, wherein the first and second regions are associated via a disulfide bond.

27. The conjugate according to claim 26, wherein the second region further comprises a nucleic acid.

28. The conjugate according to claim 25, in the form of a fusion protein.

29. The conjugate according to claim 25, wherein the second region comprises a functional or regulatory protein.

30. The conjugate according to claim 25, wherein the second region comprises an antigen.

31. The conjugate according to claim 25, wherein the second region comprises a DNA binding domain.

32. The conjugate according to claim 31, wherein the second region further comprises a nucleic acid.

33. The conjugate according to claim 31, wherein the DNA binding domain is from a histone protein or a transcription factor.

34. The conjugate according to claim 33, wherein the transcription factor is GAL4.

35. The conjugate according to claim 25, wherein the second region further comprises a nucleic acid.

36. The conjugate according to claim 25, for use in an expression system.

37. The conjugate according to claim 25, provided in a pharmaceutically-acceptable carrier.

38. A method for preparing a conjugate of claim 25, comprising:

(i) culturing a host cell transformed with an expression vector comprising a nucleic acid encoding the conjugate of claim 25 under conditions which provide for the expression of the conjugate within the host cell; and

(ii) recovering the conjugate by affinity purification under non-denaturing conditions.

39. The method according to claim 38, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.

40. A conjugate prepared by a method comprising the steps:

(i) culturing a host cell transformed with an expression vector comprising a nucleic acid encoding the conjugate of claim 25 under conditions which provide for the expression of the conjugate within the host cell; and

(ii) recovering the conjugate by affinity purification under non-denaturing conditions.

41. The conjugate prepared according to claim 40, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.

42. A method for the treatment or prevention of a condition selected from the group consisting of cancer, genetic disease, bacterial infection and viral infection, said method comprising administering an effective amount of a conjugate of claim 25 to a person or animal in need of such treatment, wherein the second region of the conjugate comprises a moiety useful in treating or preventing said condition.

---